MRG-229

MRG-229 is a **second-generation synthetic oligonucleotide** designed as a mimic of microRNA-29 (miR-29), a microRNA that is found at abnormally low levels in multiple pathological fibrotic conditions[1][5][7][10][11]. It is chemically modified for increased stability and is conjugated to a PDGFbetaR-specific bicyclic peptide (BiPPB) for targeted cellular internalization[3][4][5]. MRG-229 acts as a **microRNA modulator**, aiming to restore miR-29 levels to suppress fibrosis-associated gene expression, thereby reducing collagen and extracellular matrix protein deposition, regulated upstream through the **transforming growth factor beta (TGF-β) pathway** and other profibrotic mechanisms[1][5][9]. Preclinical studies have demonstrated robust antifibrotic activity, favorable safety, and a lack of clinically significant toxicity in animal models[2][5][12]. The molecule was developed primarily for the treatment of **idiopathic pulmonary fibrosis (IPF)**, but development for this indication was discontinued in preclinical stage as of July 2024[1].

Other names

miR-29 mimicmiR29 mimicmiR 29 mimicsecond-generation miR-29 mimic